Totus Medicines Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
37
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$66M
- Investors
-
5
Totus Medicines General Information
Description
Developer of chemical biology technologies designed to create therapeutics for untreatable diseases. The company's technology uses the power of covalent bonding and a proprietary technology platform for high-throughput drug discovery, enabling pharmaceutical developers to convert genetic discoveries into real drugs to treat cancer, Alzheimer's, infectious diseases, and even aging.
Contact Information
Website
www.totusmedicines.comCorporate Office
- 1480 64th Street
- Emeryville, CA 94608
- United States
Corporate Office
- 1480 64th Street
- Emeryville, CA 94608
- United States
Totus Medicines Timeline
Totus Medicines Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC (Series B) | 15-Dec-2023 | $66M | Completed | Startup | ||
| 2. Early Stage VC (Series A2) | 09-Dec-2021 | Completed | Pre-Clinical Trials | |||
| 1. Seed Round | 01-Jan-2020 | $1000K | $1000K | Completed | Startup |
Totus Medicines Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-2 | ||||||||
| Series A-1 |
Totus Medicines Comparisons
Industry
Financing
Details
Totus Medicines Competitors (6)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| BellBrook Labs | Venture Capital-Backed | Madison, WI | ||||
| Larimar Therapeutics | Formerly VC-backed | Bala Cynwyd, PA | ||||
| MindMed (Pharmaceuticals and Biotechnology) | Formerly VC-backed | New York, NY | ||||
| Conagen | Corporate Backed or Acquired | Bedford, MA | ||||
| Cambrex | Private Equity-Backed | East Rutherford, NJ |
Totus Medicines Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Totus Medicines Patents
Totus Medicines Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023240100-A1 | Crystalline forms and salts of a pi3k inhibitor and methods of making and methods of use thereof | Pending | 24-Mar-2022 | ||
| EP-4308121-A1 | Therapeutic conjugates | Pending | 18-Mar-2021 | ||
| US-20240228500-A1 | Therapeutic conjugates | Pending | 18-Mar-2021 | ||
| EP-4236984-A1 | Polypeptide compositions and methods for use | Pending | 02-Nov-2020 | ||
| US-20230407270-A1 | Polypeptide compositions and methods for use | Pending | 02-Nov-2020 | C12N9/0069 |
Totus Medicines Executive Team (15)
| Name | Title | Board Seat |
|---|---|---|
| Neil Dhawan Ph.D | Chief Executive Officer, Co-Founder, Head of Research & Development and Board Member and Chief Scientific Officer | |
| Daisy Chhokar | Chief People Officer | |
| Tom Knudsen | Chief Business Officer | |
| Jimmy Blair Ph.D | Co-Founder & Vice President of Platform Innovation Chemical Biology | |
| Nassim Usman Ph.D | Chief Executive Officer, President and Board Member |
Totus Medicines Board Members (11)
| Name | Representing | Role | Since |
|---|---|---|---|
| Ali Farahanchi Ph.D | DHVC | Board Member | |
| Connor McDermott | Northpond Ventures | Board Member | |
| Hope Rugo | Self | Board Member | |
| Jason Pontin | Self | Co-Founder & Board Member | |
| John Hamer Ph.D | DCVC Bio | Board Member |
Totus Medicines Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Totus Medicines Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Camford Capital | Venture Capital | Minority | ||
| DCVC Bio | Venture Capital | Minority | ||
| DHVC | Venture Capital | Minority | ||
| Northpond Ventures | Venture Capital | Minority | ||
| Social Impact Capital | Venture Capital | Minority |
Totus Medicines FAQs
-
When was Totus Medicines founded?
Totus Medicines was founded in 2019.
-
Who is the founder of Totus Medicines?
Neil Dhawan Ph.D, Jimmy Blair Ph.D, and Jason Pontin are the founders of Totus Medicines.
-
Who is the CEO of Totus Medicines?
Neil Dhawan Ph.D and Nassim Usman Ph.D are the CEOs of Totus Medicines.
-
Where is Totus Medicines headquartered?
Totus Medicines is headquartered in Emeryville, CA.
-
What is the size of Totus Medicines?
Totus Medicines has 37 total employees.
-
What industry is Totus Medicines in?
Totus Medicines’s primary industry is Drug Discovery.
-
Is Totus Medicines a private or public company?
Totus Medicines is a Private company.
-
What is Totus Medicines’s current revenue?
The current revenue for Totus Medicines is .
-
How much funding has Totus Medicines raised over time?
Totus Medicines has raised $107M.
-
Who are Totus Medicines’s investors?
Camford Capital, DCVC Bio, DHVC, Northpond Ventures, and Social Impact Capital have invested in Totus Medicines.
-
Who are Totus Medicines’s competitors?
BellBrook Labs, Larimar Therapeutics, MindMed (Pharmaceuticals and Biotechnology), Conagen, and Cambrex are some of the 6 competitors of Totus Medicines.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
